NeuroKinetic Medical stops Stage I & II pressure injuries before they progress — using proprietary electrical stimulation proven in 412-patient RCT trials across hospital, SNF, and home settings.
Navigate to any section to learn more about who we are, why this moment matters, what Prelivia does, and how it's proven.
Whether you’re a clinician, health system leader, or investor — we’d like to talk.
Get in touchFounded on 15+ years of electrical stimulation science, cleared by the FDA and Health Canada, and now executing on US commercial launch.
NeuroKinetic Medical is a medtech company transforming outcomes for patients at risk of pressure injuries — a costly, largely preventable clinical burden affecting millions of patients annually across hospital, long-term care, and home health settings.
Our flagship platform, Prelivia™, targets Stage I and Stage II pressure wounds — the 98.7% of pressure injuries that are still reversible — before they progress to the costly, unreimbursed Stage III and IV events that devastate patients and health system finances alike.
Built on 15+ years of electrical stimulation IP through our acquisition of Rehabtronics Inc., and cleared by the FDA and Health Canada, we are now executing on US commercial launch while advancing the next generation of the platform. Phase 1 is pressure injury prevention — the same proven technology applies to venous ulcers and broader wound management.
Explore our clinical evidence, platform features, or reach out directly.
Four forces have aligned to make NeuroKinetic not just possible, but necessary — today. Each is a structural tailwind. Together, they create an extraordinary and time-sensitive window.
Edge technology and AI inference is now part of hospital and SNF infrastructure — creating the connected, sensor-enabled environment that NeuroKinetic leverages for monitoring and intervention. This infrastructure tailwind reduces deployment friction and accelerates adoption.
CMS penalties and litigation costs now make pressure injuries a P&L line item, not just a QA metric. New regulations extend penalties to Stage II injuries. The average nursing home pressure ulcer lawsuit pays out $500K+. A mid-size hospital in the worst HACRP quartile loses $3M+ per year in Medicare revenue alone.
Adults 65+ will exceed 20% of the US population by 2030. ICU admissions, post-surgical patients, and SNF long-stay residents are all rising. Medicare faces insolvency within 7 years — yet pressure injury costs continue to grow unchecked, making prevention one of the highest-yield interventions available to health systems today.
Nurse-to-patient ratios are at historic lows — frontline automation of intervention and monitoring is no longer optional. Under current protocols, a 160-bed hospital needs 10 nurses working 24/7 for pressure injury management alone. With Prelivia, the same preventive outcome requires approximately 10 minutes of nursing time per patient per session.
Platform features built to solve every one of these problems directly.
A bedside durable unit plus proprietary single-use consumable pads — FDA 510(k) cleared and deployable in hospital, long-term care, and home settings with minimal nursing burden.
Prelivia targets the 98.7% of pressure injuries that are still reversible — before they advance to Stage III and IV. It works in every setting, with every patient population, with 100% patient acceptance in all clinical trials.
Stops Stage I & II pressure wounds from progressing to costly, unreimbursed Stage III & IV events. Intervenes before visible breakdown — the 98.7% window where injuries are still reversible.
Addresses the sacrum and buttocks — 59% of all pressure wound sites — with the current form factor. Electrical stimulation restores blood flow and oxygenation to at-risk tissue, preventing ischemic injury before it forms.
Electrical stimulation works regardless of staffing ratios or nurse compliance. ~10 minutes of nursing time per patient vs. 2+ hours for traditional turning protocols. A critical advantage in understaffed SNFs and hospitals.
Portable and designed for ease-of-use across hospital, long-term care, remote, and home healthcare settings. Minimal training burden — 250 nurses trained to date — with 100% patient acceptance in all clinical trials.
Roadmap includes comprehensive wound and venous ulcer management — significantly expanding the addressable market beyond pressure injuries. The same proven technology, broader application.
8 patents issued, 2 pending. 5 peer-reviewed publications. 80% less tissue injury in pre-clinical and clinical studies. 28% increase in tissue oxygenation (spO₂). Zero pressure injuries in treated patients across all completed trial arms.
Our clinical team will walk you through the platform, share outcomes data for your patient population, and support your evaluation process.
Request a demoA rigorous, peer-reviewed evidence base supporting the safety and efficacy of Prelivia — from pre-clinical studies through a 412-patient prospective RCT across 3 Magnet-designated hospital systems.
Animal & human studies completed. 68 patients across ICU, Acute & LTAC settings. Published in Annals of Biomedical Engineering and Journal of Applied Physiology. 28% increase in tissue oxygenation. 80% reduction in tissue damage.
Randomized controlled trial across 3 Magnet-designated hospital systems. 87% HAPI reduction, Stage II+. 91% sensitivity at 18 hours. Zero pressure injuries in treated patients across all completed trial arms. 100% patient acceptance.
Core science peer-reviewed and replicated. RCT submitted to WOUND journal — peer review in progress. IRB approved. NCT registered.
Understanding the biology is what makes Prelivia's approach so compelling. Intervention must happen before visible breakdown — that's the 98.7% window that current care completely misses.
Sustained pressure on soft tissue restricts blood and oxygen supply. Within as little as 2 hours, tissue begins to die. This is an ischemic injury — also called a deep tissue injury — and it forms below the surface before any visible skin change appears.
The area of damaged tissue grows as ischemia deepens. This is the critical window — Stage I and II — where 98.7% of pressure injuries still exist and are still reversible. This is exactly where Prelivia intervenes.
Ischemic injury progresses until skin and dermal layers fail. A large open wound is exposed. At this point, CMS pays $0 in reimbursement and treatment costs average $125K+ per case. Prevention is the only viable strategy.
The Prelivia durable unit sits at the bedside and delivers optimized intermittent electrical stimulation through proprietary single-use pads placed on at-risk tissue areas — primarily the sacrum and buttocks, which account for 59% of all pressure wound sites.
Single-use proprietary pads consumed per treatment. Placed on sacrum and buttocks — the highest-risk anatomical sites. Changed per protocol. No substitution possible — creates a durable recurring revenue stream alongside the durable unit.
Optimized intermittent electrical stimulation restores blood flow and oxygenation to at-risk tissue, preventing ischemic injury before it forms. The mechanism is simple, proven, and deeply validated across pre-clinical and clinical settings.
Per 300-bed hospital deployment — first-year analysis
Full clinical dossier, peer-to-peer investigator discussions, or facility evaluation support — we’re ready.
Contact medical affairsCompetition is fragmented, reactive, and single-point. NeuroKinetic is the only end-to-end AI platform for pressure injury prevention and management — with a compounding moat of IP, data, regulatory trust, and clinical relationships.
Prelivia stops injuries from forming. Every competitor — wound dressings, alternating pressure mats, turning protocols — treats symptoms after the fact. That is a fundamentally inferior economic proposition for health systems facing $0 CMS reimbursement on Stage III/IV wounds.
Electrical stimulation works regardless of staffing ratios or nurse compliance. No repositioning schedules. No reliance on overtaxed nursing staff. This is the critical advantage in understaffed SNFs and hospitals where manual protocols routinely fail under real-world conditions.
No current competitor offers a solution that is portable across clinical settings. Prelivia works in acute care hospitals, SNFs, long-term care, and home health — a single platform that follows the patient across the entire care continuum.
FDA 510(k) cleared and ISO certified. 8 patents issued, 2 pending — 15+ years of foundational electrical stimulation IP acquired through Rehabtronics Inc. 5 peer-reviewed publications. Commercially deployable today in the US and Canada.
| Solution | Prevents Injury | Adaptive | No Staff Reliance | Recurring Revenue | SNF-Ready |
|---|---|---|---|---|---|
| Prelivia™ (NK) | ✓ | ✓ | ✓ | ✓ | ✓ |
| Alternating pressure mat | ~ | — | — | ~ | ~ |
| Manual turning protocols | ~ | — | — | — | ✓ |
| Wound dressings (reactive) | — | — | — | ✓ | ✓ |
| Vibration/offloading devices | ~ | — | ~ | — | ~ |
87% HAPI reduction. 3.28× ROI. 5 peer-reviewed publications. The data backs every claim.
Clinical depth + commercial execution + technology leadership — the three capabilities that matter most in medtech commercialization, united in one founding team.
We’re building a category-defining company. Reach out to discuss clinical collaborations, commercial partnerships, or career opportunities.
Get in touchPaid pilots, strategic industry relationships, and regulatory clearances across three jurisdictions — traction that validates both clinical efficacy and commercial readiness.
Whether you’re a health system, device company, distributor, or research institution — we’d like to hear from you.
Contact usWhether you’re a clinician, investor, health system leader, or strategic partner — we’d like to hear from you.